Postmenopausal Osteoporosis - Pipeline Insight, 2026

DelveInsight's, "Postmenopausal Osteoporosis - Pipeline Insight, 2026" report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in Postmenopausal Osteoporosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Postmenopausal Osteoporosis: Understanding

Postmenopausal Osteoporosis: Overview

Postmenopausal osteoporosis (PMO) is a skeletal disorder characterized by reduced bone mass, deterioration of bone microarchitecture, and decreased bone strength, resulting in an increased risk of fragility fractures. It is particularly associated with the menopausal transition, when accelerated bone loss occurs because of declining estrogen levels. Bone loss is especially important during the early postmenopausal period and contributes to an increased risk of vertebral, hip, and other osteoporotic fractures with advancing age.

The primary cause of postmenopausal osteoporosis is estrogen deficiency associated with menopause, which accelerates bone loss. Additional risk factors include older age, genetic predisposition, low body weight, physical inactivity, smoking, excessive alcohol or caffeine consumption, inadequate calcium and vitamin D intake, and insufficient sunlight exposure. Secondary contributors can include certain systemic diseases and medications that adversely affect bone metabolism. Genetic factors may also account for a substantial proportion of an individual's susceptibility to postmenopausal osteoporosis.

Bone is continuously remodeled through coordinated osteoclastic bone resorption and osteoblastic bone formation. After menopause, reduced estrogen levels increase osteoclast production and activity, resulting in excessive bone resorption that is not adequately compensated by new bone formation. This imbalance causes loss of trabecular and cortical bone, deterioration of bone microarchitecture, and progressive reduction in bone mineral density (BMD). The resulting reduction in bone strength makes postmenopausal women more susceptible to fragility fractures.

Diagnosis of postmenopausal osteoporosis primarily relies on bone mineral density assessment using dual-energy X-ray absorptiometry (DXA/DEXA), particularly at the hip and spine. A T-score of -2.5 or lower is generally used to define osteoporosis, whereas a T-score between -1.0 and -2.5 indicates osteopenia. Assessment of fracture risk can also incorporate clinical factors such as age, previous fractures, smoking, alcohol consumption, glucocorticoid exposure, and BMD using tools such as FRAX, which estimates the 10-year probability of hip and major osteoporotic fractures.

Treatment of postmenopausal osteoporosis combines lifestyle measures, nutritional supplementation, and pharmacological therapy according to fracture risk. Adequate

calcium and vitamin D intake, weight-bearing and resistance exercise, smoking cessation, limiting alcohol consumption, and fall prevention are important components of management. Pharmacological treatments include anti-resorptive agents, such as bisphosphonates and denosumab, which reduce bone resorption, and anabolic agents, such as teriparatide and abaloparatide, which stimulate new bone formation. Menopausal hormone therapy may also help preserve BMD in selected women, particularly around the time of menopause, following individualized assessment of its benefits and risks.

"Postmenopausal Osteoporosis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postmenopausal Osteoporosis pipeline landscape is provided which includes the disease overview and Postmenopausal Osteoporosis treatment guidelines. The assessment part of the report embraces, in depth Postmenopausal Osteoporosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postmenopausal Osteoporosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Postmenopausal Osteoporosis R&D. The therapies under development are focused on novel approaches to treat/improve Postmenopausal Osteoporosis.

Postmenopausal Osteoporosis Emerging Drugs Chapters

This segment of the Postmenopausal Osteoporosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postmenopausal Osteoporosis Emerging Drugs

• AGA2118: Angitia Biopharmaceuticals

AGA2118 is a bispecific antibody that targets sclerostin and DKK1 and is in clinical development for the treatment of osteoporosis. Sclerostin and DKK1 are two critical, negative regulators of WNT signaling in osteoblasts and of bone metabolism. By targeting both proteins, AGA2118 is thought to prevent compensatory increase of either agent, aiming to improve the magnitude of bone mineral density gains in osteoporotic patients. Angitia is developing AGA2118 in OLYMPUS (Osteoporosis Longitudinal multi-Year prograM to evaluate Postmenopausal women at risk for fractUreS), which is currently under investigation in the ARTEMIS Phase II trial (A Phase II Randomized Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS).

• HMM-910: Help Therapeutics

HMM-910 is a human umbilical cord-derived mesenchymal stem cell (MSC) therapy developed by HELP Therapeutics for the treatment of postmenopausal osteoporosis. The therapy is administered by intravenous infusion and is being evaluated in postmenopausal women with osteoporosis who are at high risk of fracture. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Osteoporosis.

Postmenopausal Osteoporosis: Therapeutic Assessment

This segment of the report provides insights about the different Postmenopausal Osteoporosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Postmenopausal Osteoporosis

There are approx. 13+ key companies which are developing the therapies Postmenopausal Osteoporosis. The companies which have their Postmenopausal Osteoporosis drug candidates in the most advanced stage, i.e. Phase II include, Angitia Biopharmaceuticals and others.

• Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Postmenopausal Osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Postmenopausal Osteoporosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postmenopausal Osteoporosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postmenopausal Osteoporosis drugs.

Postmenopausal Osteoporosis Report Insights

• Postmenopausal Osteoporosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Postmenopausal Osteoporosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Postmenopausal Osteoporosis drugs?
• How many Postmenopausal Osteoporosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postmenopausal Osteoporosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Postmenopausal Osteoporosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Postmenopausal Osteoporosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Angitia Biopharmaceuticals
• Help Therapeutics
• EnteraBio
• Shenzhen Salubris Pharmaceuticals Co., Ltd.

Key Products

• AGA2118
• HMM 910
• EB613
• SAL056